Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Older Women With Early Cervical Cancer Are Less Likely to Have Surgery

August 6th 2012

Among patients with early-stage cervical cancer, women aged greater than 65 years are less likely than younger women to be treated with surgery as compared with chemoradiation.

Maintenance Erlotinib Fails to Improve Survival in Ovarian Cancer

July 31st 2012

Erlotinib given as a maintenance therapy did not improve PFS or OS in patients with epithelial ovarian cancer who had received first-line platinum-based chemotherapy.

Multidisciplinary Approaches Are Needed in Ovarian Cancer

July 23rd 2012

While ovarian cancer survival rates have improved slightly since the 1970s, the overall five-year survival for patients diagnosed with the tumor type lags behind the average rate of all cancers.

Dr. Bast Discusses Biomarkers for Ovarian Cancer

July 19th 2012

Dr. Robert Bast, from the MD Anderson Cancer Center, Discusses New Biomarker Panels for Ovarian Cancer Screening.

Heidi Donovan Discusses Prioritizing Symptoms

July 13th 2012

Heidi Donovan from the University of Pittsburgh School of Nursing Discusses Prioritizing Symptoms

Current Issues in Gynecologic Oncology: A Discussion With John Curtin, MD

July 13th 2012

Many contemporary issues in the US healthcare system affect clinicians in all areas of medicine. Some issues are even more specific to the field of gynecologic oncology.

Close Call for Cost-Effectiveness of Bevacizumab in Ovarian Cancer

July 9th 2012

Recent clinical and economic studies have suggested that ovarian cancer regimens containing bevacizumab could fall within the boundaries of cost-effectiveness, at least for some patients.

Regimen in Recurrent Endometrial Cancer Challenged: TAP Not Superior to Less-Toxic, Two-Drug Therapy

July 3rd 2012

A summary of findings from the 43rd Annual Meeting on Women's Cancer with the potential to impact routine management of women with pelvic malignancies.

Mutations Pass From Primary to Recurrent Endometrial Cancer

June 26th 2012

Most recurrent endometrial tumors have the same PI3K/Akt mutation profile as found in the primary tumor.

Breast Cancer and Early-Onset Menopause

June 14th 2012

Whether surgically or medically induced, early menopause forces women to deal with a host of emotional, physical, and practical issues.

Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer

June 2nd 2012

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Dr. Davidson on Screening for Ovarian Cancer

May 23rd 2012

Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, on Screening for Ovarian Cancer

PARP Inhibitors Intriguing Despite Research Setbacks

April 26th 2012

Despite initial disappointing findings on overall survival, PARP inhibitors remains under active investigation for patients with ovarian cancer.

Improved Survival in Women With Invasive Epithelial Ovarian Cancer and Germline BRCA Gene Mutations

March 26th 2012

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Birrer on the Ovarian Cancer Avastin OS Benefit

March 2nd 2012

Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit

Benefits of Bevacizumab in Ovarian Cancer Clarified

March 1st 2012

Bevacizumab has failed to demonstrate statistically significant improvements in OS for women with recurrent ovarian cancer in 2 recent clinical trials.

Conference Features Debates on Clinical Controversies

February 21st 2012

The 9th International Symposium on Ovarian Cancer and Other Gynecologic Malignancies conference will bring professionals in the field up to date on the latest research into ovarian, uterine, cervical, and endometrial cancers.

Dr. Birrer Discusses the GOG0218 and ICON7 Trials

February 2nd 2012

Dr. Michael Birrer, from Massachusetts General Hospital Cancer Center, Discusses the GOG0218 and ICON7 Trials

BRCA1 and BRCA2 Mutations Yield Better Prognosis in Ovarian Cancer Patients

January 25th 2012

Patients with ovarian cancer who express BRCA1/2 mutations demonstrated a better overall survival after 5 years.

Brain Metastasis Common in Ovarian Cancer

January 20th 2012

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.